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The emerging role of histone lysine
demethylases in prostate cancer
Francesco Crea1*, Lei Sun3, Antonello Mai4, Yan Ting Chiang1, William L Farrar3,
Romano Danesi2 and Cheryl D Helgason1,5*
Abstract
Early prostate cancer (PCa) is generally treatable and associated with good prognosis. After a variable time, PCa
evolves into a highly metastatic and treatment-refractory disease: castration-resistant PCa (CRPC). Currently, few
prognostic factors are available to predict the emergence of CRPC, and no curative option is available. Epigenetic
gene regulation has been shown to trigger PCa metastasis and androgen-independence. Most epigenetic studies
have focused on DNA and histone methyltransferases. While DNA methylation leads to gene silencing, histone
methylation can trigger gene activation or inactivation, depending on the target amino acid residues and the
extent of methylation (me1, me2, or me3). Interestingly, some histone modifiers are essential for PCa tumor-
initiating cell (TIC) self-renewal. TICs are considered the seeds responsible for metastatic spreading and androgen-
independence. Histone Lysine Demethylases (KDMs) are a novel class of epigenetic enzymes which can remove
both repressive and activating histone marks. KDMs are currently grouped into 7 major classes, each one targeting
a specific methylation site. Since their discovery, KDM expression has been found to be deregulated in several
neoplasms. In PCa, KDMs may act as either tumor suppressors or oncogenes, depending on their gene regulatory
function. For example, KDM1A and KDM4C are essential for PCa androgen-dependent proliferation, while PHF8 is
involved in PCa migration and invasion. Interestingly, the possibility of pharmacologically targeting KDMs has been
demonstrated. In the present paper, we summarize the emerging role of KDMs in regulating the metastatic
potential and androgen-dependence of PCa. In addition, we speculate on the possible interaction between KDMs
and other epigenetic effectors relevant for PCa TICs. Finally, we explore the role of KDMs as novel prognostic factors
and therapeutic targets. We believe that studies on histone demethylation may add a novel perspective in our
efforts to prevent and cure advanced PCa.
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Introduction: prostate cancer epigenetics
It has been estimated that 240,890 men in the US devel-
oped prostate cancer (PCa) during 2011 [1]. In western
countries, PCa is the most common male neoplasm, and
the second leading cause of male cancer-related deaths.
Unlike other common neoplasms (lung and colon can-
cer), PCa incidence has increased in the past few years.
PCa is a double-stage disease, which usually starts as a
treatable and poorly aggressive neoplasm. Early PCa can
be treated by a combination of surgery, radiation and
hormonal therapy [2]. The last option includes castra-
tion and pharmacological disruption of androgen-
receptor (AR) signalling, which is a major proliferation
stimulus for prostate cells. After a variable time, PCa
may evolve into an aggressive neoplasm, usually referred
to as castration-resistant PCa (CRPC) [3]. CRPC is asso-
ciated with metastasis to lung, brain, liver and bones in
90% of the cases, and displays an 18-month median sur-
vival [4]. CRPC is resistant to conventional treatments,
and chemotherapy itself can only delay its progression.
Currently, few molecular targets are available to treat
CRPC [3], and few prognostic factors are associated with
PCa recurrence and progression [5]. Thus, the identifica-
tion of novel prognostic factors and therapeutic targets
is highly needed in this field.
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In the past decade, it has become increasingly evident
that epigenetic gene regulation plays a crucial role in
PCa initiation and progression. Epigenetics refers to all
heritable changes which are not dependent on modifica-
tions of DNA primary sequence (summarized in Figure 1)
[6]. The two classical epigenetic marks are DNA
methylation and histone post-translational modifications
(HPTMs). DNA methyltransferases (DNMTs) target cyto-
sine residues, particularly on gene promoter regions,
thereby triggering gene silencing. Several tumor suppres-
sor genes are silenced by DNMTs in PCa, including pro-
apoptotic, anti-metastatic and growth-inhibiting factors
[7]. HPTMs orchestrate chromatin transcriptional activity,
through a complex “histone code” [8]. The basic chroma-
tin structure is represented by the nucleosome (Figure 1)
consisting of 140-160 base pairs of DNA wrapped around
a repetitive nucleosome core composed of four couples of
histones H2A, H2B, H3 and H4. N-terminal histone tails
protrude from this structure and may be targeted by
several histone modifiers including methyltransferases/
demethylases and acetyltransferases/deacetylases. Each
modification may loosen or tighten local DNA-histone
binding, thereby contributing to gene reactivation or si-
lencing. For example, histone acetylation is always
coupled to gene activation, while histone deacetylation
leads to gene silencing [9]. Histone methylation may
occur on different lysine residues, with opposite effects:
histone H3-lysine 4 dimethylation (H3K4me2) and
H3K36me2 are activating marks, while H3K27me2/3
and H3K9me2/3 are repressive marks [8].
HPTMs have been linked to PCa metastasis and/or
androgen-independence by several studies. For example,
specific histone deacetylases (HDACs) are over-
expressed in androgen-independent PCa, and may con-
tribute to chemo-resistance [10]. HDAC inhibitors are
able to re-sensitize PCa cells to hormonal therapy [11],
and are currently being tested on CRPC patients [12].
Polycomb (PcGs) and Trithorax (TrxGs) group genes
encode for epigenetic modifiers with opposite roles in
embryo development and cancer. Both PcG and TrxG
proteins are organized into multimeric complexes, medi-
ating specific HPTMs (Figure 1). In particular, Polycomb
repressive Complexes (PRCs) are involved in gene silen-
cing, through histone H2A ubiquitination (PRC1) and
Figure 1 Epigenetic mechanisms of gene silencing and activation. Nucleosomes are composed of DNA (black strip) wrapped around 4
couples of core histones. Histone tails and DNA cytosines may be modified by several enzymes (orange circles), which add or remove epigenetic
marks. Local gene function results from the combined interaction of all epigenetic enzymes. Me, methylation; K, lysine; ub, ubiquitination; DNMT,
DNA methyltransferase; PRC, Polycomb repressive complex; G9a, histone H3K9 methyltransferase; HAT, histone acetyltransferase; HDAC, histone
deacetylase; KDM, lysine-specific demethylases.
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H3K27 trimethylation (PRC2) [9]. PcG members BMI1
and EZH2 contribute to PCa metastasis through their
gene silencing function [13]. Mapping H3K27me3 on
specific loci, a PRC2-dependent gene signature has been
associated with poorer prognosis in advanced PCa [14].
PRC-dependent gene silencing may be counteracted by
H3K4me2, mediated by TrxGs [9]. Interestingly, some
members of this class are emerging as tumor suppres-
sors in PCa [15].
In 2004, a human lysine-specific demethylase (KDM)
was described for the first time [16]. Since then, several
KDM isoforms were discovered, and characterized as
epigenetic enzymes [17]. KDMs may counteract different
histone methyltransferases (like PcG or TrxG members),
thereby activating or repressing gene expression (Fig-
ure 1). Since HPTMs are known to orchestrate critical
functions of PCa cells, it is conceivable that KDMs are
key players of those processes. In this review, we will
summarize emerging evidence on the role of KDMs in
PCa progression, and will propose their use as prognos-
tic factors and therapy targets.
Histone demethylases and prostate cancer
Until the discovery of KDM1A (LSD1), histone lysine
methylation had been long considered an irreversible
epigenetic mark. KDM1A specifically demethylates
H3K4me1/2 [16]. Currently, two KDM1 isoforms have
been described (KDM1A and B); both are flavin-
dependent demethylases with the same histone residue
specificity [17]. Since H3K4me2 is an active mark,
KDM1 favours gene silencing. However, when recruited
by androgen receptor (AR), KDM1A loses its capability
to demethylate H3K4me1/2 and instead catalyzes the
demethylation of H3K9me1/2, two repressive marks,
thus acting as a co-activator [18]. A second class of
KDMs is represented by the Fe2+/oxoglutarate-
dependent enzymes, containing a characteristic Jumonji
C (JmjC) domain [19]. Those KDMs are divided into six
clusters (KDM 2-7), most of which include at least two
members [17]. Each cluster is characterized by one or
more target histone residues. For example, KDM2 and
KDM5 clusters are mainly involved in removing active
marks (H3K4me2 and H3K36me2), thereby triggering
gene silencing [20]. To the contrary, KDM3 and KDM6
mediate gene reactivation [21]. In particular, KDM3
genes remove H3K9me2, a repressive mark catalyzed by
the putative oncogene G9a [22]. KDM6 removes
Polycomb-dependent H3K27me3 [9], thereby playing a
potential tumor-suppressive function in PCa. Finally, the
KDM4 cluster includes both activating and repressive
enzymes [17]. Due to the large number of family mem-
bers exhibiting different functions, it is not surprising
that KDMs may play oncogenic or tumor-suppressive
roles in several neoplasms. For example, a census of
frequently mutated cancer genes identified KDM5A, 5C
and 6A are implicated in several malignancies, including
acute myeloid leukemia, esophageal, renal and squamous
cell carcinomas [18]. Since KDMs display a wide variety
of “aliases” in the literature, we summarized in Table 1
the most common names for each gene discussed in this
manuscript.
KDM1A, the most deeply studied lysine-specific
demethylase, is a putative oncogene in several neoplasms
including PCa [17]. Its oncogenic function partially
resides on the ability to trigger Myc-dependent transcrip-
tion [23], while inhibiting p53 pro-apoptotic function [24].
In PCa, KDM1A mainly acts as an AR co-activator [25].
In complex with AR, KDM1A, after histone H3 threonine
6 phosphorylation by protein kinase C β1 (PKCβ1) [26],
changes its specificity from H3K4me1/2 to H3K9me1/2,
thereby switching its role from co-repressor to co-
activator [27]. Interestingly, pargyline blocked demethyla-
tion of H3K9me1/2 during androgen-induced transcrip-
tion [25], and the tranylcypromine derivatives NCL-1 and
NCL-2 [28] reduced androgen-dependent proliferation in
PCa cells through KDM1A inhibition. In some circum-
stances, KDM1A may also act as an AR co-repressor. In
the presence of high androgen concentrations, AR recruits
LSD1 to mediate AR gene silencing [29]. This negative
feedback loop is probably disrupted in CRPC, where low
androgen levels favour AR over-expression. In addition,
high KDM1A expression in primary PCa predicts higher
risk of relapse after prostatectomy [30]. Thus, it is con-
ceivable that KDM1A triggers androgen-dependent
proliferation and recurrence after therapy. It is worth
Table 1 Formal names and aliases of KDMs cited in this
manuscript. Aliases are from GeneCards website (www.
genecards.org)
GENE NAME ALIASES
KDM1A LSD1, BHC110, AOF2
KDM1B LSD2, AOF1
KDM2A JHDM1A, CXXC8, FBL7
KDM3A TSGA, JHDM2A,JMJD1A2, JHMD2A
KDM3B JHDM2B, NET22
KDM4A JHDM3A, JMJD2
KDM4B JHDM3B, JMJD2B
KDM4C GASC1, JHDM3C, JMJD2C
KDM5A JARID1A, RBBP2
KDM5B JARID1B, RBBP2H1A, PLU1, CT31
KDM5C JARID1C, SMCX, XE169
KDM6A UTX
KDM6B JMJD3
KDM7 JHDM1D
PHF8 JHDM1F, ZNF422
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mentioning that some authors did not manage to confirm
a significant correlation between KDM1A expression and
PCa progression [31]. This may be due to smaller sample
size, and/or differences in technologies employed. Other
KDMs were identified as AR-co-activators (Table 2), but
their role in PCa progression has not been clarified. One
of them (KDM4C) co-operates with KDM1A to remove
H3K9me marks, thereby activating AR targets [32]. Inter-
estingly, KDM4C is required for cancer cell proliferation
[33], and its expression is higher in CRPC, compared to
hormone sensitive tumors and prostate hyperplasia [31].
Further studies are required to elucidate the relationship
between AR, KDM1A/4C and PCa transition to an
androgen-independent state, but these preliminary data
indicate that those genes are promising therapy targets to
inhibit early PC progression.
Some KDMs have been implicated in PCa metastatic
spreading. A systematic knockdown of epigenetic
enzymes in PCa cells identified PHF8 as a novel onco-
gene [34]. PHF8 contributes to gene activation through
H3K9me1/2, H3K27me2, and H4K20me1 demethylation.
It is over-expressed in PCa compared to normal pros-
tate. PHF8 inhibition reduces proliferation of AR-
positive and AR-negative PCa cells. In addition, PHF8
mediates PCa cell invasion and migration, two crucial
steps of metastatic spreading. PHF8 silencing was asso-
ciated with down-regulation of integrin-related genes.
Integrin-dependent signalling is known to mediate PCa
invasion [35]. Recent evidence indicates that members
of the KDM5/JARID cluster may also be involved in
PCa metastasis. KDM5B, which is significantly over-
expressed in local and metastatic PCa, is an AR-co-
activator [36]. KDM5C was shown to inhibit the
transcriptional activity of SMAD3, a TGFβ-dependent
transcription factor, independently of its enzymatic activ-
ity [37]. TGFβ signalling in PCa blocks early tumorigen-
esis, but paradoxically enhances metastatic spreading
[38]. Thus, KDM5C may act as an oncogene in early
PCa, but hinder metastatic spreading at later stages. Fi-
nally, the H3K27-specific demethylase KDM6B is pro-
gressively over-expressed in higher stage PCa [39].
H3K27 trimethylation is mediated by PRC2 component
EZH2, which is up-regulated in metastatic PCa cells,
and required for tissue invasion and blood dissemination
[13,40]. Although it is not clear why metastatic PCa cells
over-express two epigenetic proteins with opposite func-
tions, one possibility is that a compensatory mechanism
is activated in those cells. Alternatively, co-ordinated up-
regulation of EZH2 and KDM6B allows for selective up-
and down-regulation of specific target genes, depending
on local adaptive needs of metastatic cells. Indeed, the
metastatic process requires a certain degree of gene ex-
pression plasticity [41].
As shown in Table 2, other KDMs display up-
regulation in PCa samples, compared to non-
transformed cells [17,34]. KDM2A is down-regulated in
PCa, where it may play a tumor-suppressive function
through its role in maintaining genome integrity [28].
Very little is known on the specific cellular function of
these genes in PCa. Future studies should dissect mo-
lecular pathways linked to KDM activation or inactiva-
tion, as well prospectively investigate KDM expression
patterns in specific cancer subtypes (metastatic vs. pri-
mary; high vs. low grade; CRPC vs. hormone-sensitive
PCa). These studies will allow us to identify the most
promising therapeutic targets and prognostic factors.
Histone demethylases as prognostic factors and
therapy targets
As summarized in the previous paragraph, emerging evi-
dence indicates that KDMs play key roles in specific
steps of PCa progression and particularly in transition
from an androgen-dependent to an androgen-
independent state, as well as in metastatic spreading.
Apart from a few exceptions (KDM1A, PHF8) the mo-
lecular function of KDMs in PCa cells remains obscure.
A useful cancer biomarker may predict cancer risk,
tumor progression or response to a specific therapy [42].
Only in the first case, is over-expression in cancer vs.
normal cells required to obtain sufficient diagnostic
power. PCa prognostic factors may be used to predict
recurrence risk after prostatectomy, transition to an
androgen-independent state, or progression-free survival
after specific therapies. With very few notable excep-
tions, prognostic variables have not been correlated to
KDM expression. For this reason, we queried two inde-
pendent gene expression databases to compare KDM ex-
pression in different prostate specimens (normal vs.
Table 2 List of KDM genes described as relevant for PCa.
For gene aliases, see Table 1
GENE ROLE IN PROSTATE CANCER REF.
KDM1A Oncogene, AR co-activator, associated with higher
relapse risk
25-28
KDM2A Putative tumor suppressor, reduced expression in PCa 41
KDM3A Putative oncogene, overexpressed in PCa,
AR co-activator
30, 33
KDM4A Overexpressed in PCa 33
KDM4B Overexpressed in PCa 33
KDM4C Putative oncogene, overexpressed in CRPC, AR
co-activator
30-32
KDM5B Overexpressed in metastatic PCa, AR-co-activator 35
KDM5C Putative oncogene, overexpressed in PCa, suppresses
TGFB signalling
36
KDM6B Putative oncogene, overexpressed in metastatic PCa 38
PHF8 Putative oncogene, overexpressed in PCa, mediates
cell invasion
33
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PCa; primary vs. metastatic PCa; low- vs. high-grade; an-
drogen-dependent vs. -independent PCa). In particular,
we used a two-step strategy to validate our findings.
First, we queried an integrative genomic profiling data-
base of 218 PCa specimens generated at Memorial
Sloan-Kettering Cancer Centre (MSKCC) [43]. To valid-
ate those findings, KDM genes whose expression was
significantly modulated, according to MSKCC database,
were also investigated through analysis using the Onco-
mine database [44]. In order to reduce our false discov-
ery rate, we selected p < 0.01 as a threshold. Table 3 and
Figure 2 summarize our results. At first glance, it is evi-
dent that most KDM genes emerging from this query
have been largely overlooked by previous studies, and
may be identified as novel biomarkers. If we decide to
prioritize genes significantly associated with clinical vari-
ables in both databases, KDM1B, 4C and 5D are the best
candidates as potential biomarkers. The only gene with a
known function in PCa is KDM4C. As already described,
KDM1A and KDM4C co-operate to enhance AR tran-
scriptional activity [32]. KDM4C was also shown to con-
tribute to androgen-independence [31]. Our results
confirm the oncogenic role of KDM4C: the MSKCC
database indicates that its expression increases with
tumor stage, while Oncomine data identify a significant
KDM4C overexpression in PCa vs. normal prostate
gland (Figure 2) and in grade 3 vs. grade 2 PCa
(p = 0.002, fold change 13.125, data not shown). Based
on our analysis KDM1B is a putative oncogene, since it
is a negative prognostic marker (MSKCC database), and
it is specifically overexpressed in CRPC (Oncomine
data). Several data from our queries indicate that
KDM5D acts as an oncosuppressor in PCa. It’s down-
regulation may be involved in tumor-initiation (Figure 2),
as well as in increased tumor grade and stage (Table 3).
According to those results, its expression predicts longer
progression-free survival after prostatectomy (Table 3).
Another gene previously associated with cancer is
KDM5A. It emerges as a putative prognostic factor from
the MSKCC data, although no significant correlation
was found in the Oncomine database. Some data from
the MSKCC database concordantly suggests an onco-
genic function for KDM2B and an oncosuppressive role
for KDM4D, although we found no significant correla-
tions using the Oncomine database. In summary, our
results indicate that some KDMs may play an important
Table 3 List of KDM genes significantly up- or down-regulated in PCa clinical subtypes (MSKCC and Oncomine
databases)
Gene Clinical Variable Gene expression P value Putative function Oncomine
KDM1B Overall Survival (OS) Higher predicts shorter OS 0.0045 Oncogene In agreement
KDM2B PSA level at diagnosis Higher predicts higher PSA 0.0070 Oncogene
Gleason Score Higher predicts higher grade 0.0001
Lymph Node invasion Higher predicts invasion 0.0002
Metastasis Higher predicts higher metastatic risk 3.09E-07
Recurrence-Free Survival (RFS) Higher predicts shorter RFS 0.0066
KDM3B PSA level at diagnosis Lower predicts higher PSA 0.0004 Oncosuppressor In disagreement
Gleason Score Lower predicts higher grade 0.0066
KDM4C Metastasis Lower in non-metastatic tumors 0.0086 Oncogene In agreement
KDM4D Gleason Score Higher predicts higher grade 0.0002 Oncogene
Lymph Node invasion Higher predicts invasion 0.0019
Recurrence-Free Survival (RFS) Higher predicts shorter RFS 0.0002
Metastasis Lower in non-metastatic tumors 0.001
KDM5A Probability of recurrence after prostatectomy Higher predicts higher probability 0.002 Oncogene
KDM5D Gleason Score Higher predicts lower grade 0.0035 Oncosuppressor In agreement
Lymph Node invasion Lower predict invasion 0.0036
Metastasis Lower predicts higher metastatic risk 3.7E-5
Probability of recurrence after prostatectomy Lower predicts higher probability 0.0003
KDM7 Gleason Score Higher predicts higher grade 0.0016 ?
Lymph Node invasion Lower predicts invasion 0.0009
Recurrence-Free Survival (RFS) Higher predicts longer RFS 0.008
From the MSKCC database, we report all associations with p < 0.01, for the following clinical variables: PSA (prostate specific antigen) levels at diagnosis; Gleason
score, based on prostatectomy; lymph node invasion; metastatic risk; recurrence free survival (or probability of recurrence) after prostatectomy; overall survival.
Oncomine data are described as “in agreement” if they confirm the oncogene/oncosuppressor function deduced from the MSKCC database. Oncomine thresholds:
p < 0.01; fold-change >2.0. Oncomine data are shown in Figure 2. For gene aliases, see Table 1.
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role as novel biomarkers, particularly for prediction of
tumor-initiation, progression-free survival and androgen-
independent state.
Interestingly, KDMs may be targeted by selective small
molecule inhibitors (Figure 3), which are being actively
investigated in biochemical and pre-clinical models.
KDM inhibitors have been extensively reviewed previ-
ously [17]. Here, we will analyze their possible develop-
ment as anti-PCa agents. Based on its expression pattern
and oncogenic function, KDM1A is the most attractive
target for PCa therapy. KDM1A inhibitors include sub-
strate analogues, polyamine analogues, and inhibitors of
the mono-amino-oxidase (MAO) domain. Since the
KDM1A catalytic domain shares homology with neural
MAOs [16], pharmacological inhibitors developed as
anti-depressive agents have been employed to target
cancer cells. Unlike other KDM targeting drugs, MAO
inhibitors have already been tested for their pharmacoki-
netic and toxicity profiles, thus they can be readily trans-
lated into the clinics. However, most molecules of this
class failed to meet expectations. For example, pargyline
was first described as a valuable KDM1A inhibitor in
PCa cells after AR induction [25], but further studies
failed to confirm this observation [45,46]. Subsequently,
tranylcypromine and its analogues proved to more ef-
fectively inhibit H3K4 demethylation. In particular,
NCL-1 and NCL-2 showed 50% growth inhibiting con-
centrations ranging from 6 to 17 micromolar when
tested on androgen-independent PCa cells [47]. Interest-
ingly, tranylcypromine displayed a safe toxicity profile,
even when administered at high-intensity regimens [48].
According to our results (Table 3) and to previously
published data [17], tranylcypromine analogues may be
particularly effective to prevent PCa recurrence and
transition to an androgen-independent state. Future
studies should specifically address those points, going
beyond the simple measurement of growth inhibitory
effects. Clorgyline is another MAO inhibitor which
seems to exert anti-proliferative and pro-differentiation
activity on high grade-PCa cells [49]. This effect is in
part mediated by inhibition of growth factor signalling
and down-regulation of EZH2 methyltransferase. The
authors did not investigate its effect on KDM1A. Very
recently, the γ–pyrone namoline has been described as a
reversible KDM1A inhibitor able to inhibit LNCaP cell
proliferation, expression of the AR target genes FKBP5
and TMPRSS2, and tumor growth in a mouse PCa
model [50].
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Figure 2 KDM genes significantly modulated in PCa (Oncomine database). Genes listed in Table 3 were queried in the Oncomine database.
Significant associations are presented in this figure. PIN, prostatic intra-epithelial neoplasia. KDM1B, p < 0.001, fold-change, 2.746; KDM3B, p < 0.001,
fold-change, 2.516; KDM4C, p < 0.001, fold-change, 5.89; KDM5D, p < 0.001, fold-change, -2.178. With the exception of KDM4C, we found one
significant correlation per gene. For KDM4C, we report the most significant correlation, while the other one (tumor grade) is only quoted in the
main text.
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An interesting approach is the combination of epigen-
etic therapies. KDM1A and HDAC inhibitors showed
synergistic antitumor activity on glioblastoma cells [51].
Since HDAC inhibitors are being tested on PCa patients,
this strategy may be explored in this neoplasm too. For
example, the HDAC inhibitor vorinostat is a promising
epigenetic drug, since it also inhibits EZH2 and H3K4
demethylases at micromolar concentrations [52,53]. The
above mentioned combinatorial approach may be tested
using KDM1 and JmjC-domain demethylase inhibitors.
Unfortunately, a restricted number of potent and select-
ive inhibitors mainly for KDM4 have been developed so
far (Figure 3) [54], and none of them have been tested in
PCa. The only exception were some hydroxamic acids
described as KDM4A/4C inhibitors, that were ineffective
on PCa cells as single agents, but displayed synergistic
activity in combination with the tranylcypromine
analogue NCL-2 [55]. Since different KDMs may act as
oncogenes or tumor suppressors, the specificity issue is
of crucial importance.
Tumor-initiating cell epigenetics: is there a role
for histone demethylases?
It has been traditionally accepted that all cancer cells are
biologically equivalent with every single cell able to form
a new tumor. However, during the past few years, mount-
ing evidence has shown that a tumor is composed of het-
erogeneous cancer cells and only a subset can initiate
tumor growth (reviewed in [56]). This specific popula-
tion, termed tumor initiating cells (TICs), can self-renew
and differentiate into non-tumorigenic progeny which
make up the tumor bulk. In addition, TICs highly express
stem cell specific genes and have been observed to share
certain characteristics with normal stem cells [57,58].
This conceptual advance has very important clinical
implications, because these cells are considered to be re-
sistant to conventional therapies, such as chemotherapy
and irradiation [40,59]. TICs survive after treatment,
leading to relapse and acting as the “seeds” for metasta-
sis. Prostate TICs show higher metastatic potential than
differentiated cancer cells [60], and some TIC-specific
pathways are essential for PCa metastatization [61,62].
TICs are regulated by both genetic and epigenetic fac-
tors, such as KDMs. As described, KDM1 triggers gene
silencing by removing the methyl groups from H3K4me2
[63,64]. In a very recent study, Wang et al. developed
specific bioactive small inhibitors of KDM1A and uncov-
ered that these compounds, or specific KDM1A shRNA,
selectively targeted cancer cells with stem cell properties
that highly express the stem cell markers OCT4 and
Figure 3 Chemical structures of KDM inhibitors. The compounds cited in the text are indicated in bold.
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SOX2 [65]. However, these inhibitors displayed much
lower effects on the growth of non-TICs or normal
somatic cells. In correlation with this finding, KDM1A
protein levels are highly up-regulated in TICs and in
OCT4-positive human PCa tissues, suggesting a critical
role for KDM1A and histone H3K4 in TICs. Moreover,
high levels of KDM1A are correlated with high-risk
tumors and patient relapse after prostatectomy [30]. It has
been proposed that a combination of traditional chemo-
radiotherapy, plus TIC-specific agents could be optimal
for cancer treatment [66]. The first strategy, being effective
on the bulk tumor mass, is able to produce an objective
response, while the latter should reduce tumor recurrence
and progression. KDM1A targeting drugs may therefore
emerge as TIC-specific agents in PCa.
H3K9me2 and H3K9me3 are both silencing-associated
histone marks. As indicated in Table 2 KDM4C and
KDM3A that demethylate these marks are highly
expressed in PCa tissues, but their functions remain ob-
scure. In a study on embryonic stem (ES) cells, pluripo-
tency specific transcription factor OCT4 positively
regulates KDM4C and KDM3A expression by directly
binding to their introns [67]. Interestingly, the depletion
of either KDM results in ES cell differentiation, indicating
their requirement for the maintenance of self-renewal. In
addition, KDM4C activates the expression of Nanog,
another important stem cell-specific transcription fac-
tor, while KDM3A acts as a positive regulator for
pluripotency-associated genes, such as Tcl1, Tcfcp2l1,
and Zfp57. Although further investigation is needed to
understand how these KDMs contribute to the biology
of prostate TICs, we highly suspect that they may play
an indispensible role in regulating the stem cell-like
properties of prostate TICs. Indeed, epigenetic gene
regulation is crucial for maintaining TIC plasticity [9].
During the past few years, more KDMs have been
shown to be involved in regulating the biology of the
TIC population. As mentioned above, PHF8 [34] and
KDM5B [36] are both highly expressed in metastatic
prostate tissues and they may play important roles in
controlling the invasion and metastasis of PCa cells.
Since PCa TICs are more invasive than differentiated
cancer cells [68], it is conceivable that these KDMs are
involved in TIC metastatic potential, as shown for other
histone modifiers [40]. In addition, there is evidence
showing that KDMs functionally interact with some
other epigenetic machinery, such as the histone methyl-
transferase EZH2, a Polycomb protein essential for the
tumorigenic and metastatic potential of TICs [40,69-71].
The KDM-TIC correlation is still an interesting hypoth-
esis, which needs to be further confirmed. We believe
that future studies should investigate KDMs as regula-
tors of prostate TICs and therapeutic targets in pre-
clinical models.
Conclusions
In summary the current data suggest that various KDMs
show differential expression in PCa and are likely to play
important roles in tumor initiation and progression.
Clearly further evaluation of the specific roles of the
various KDMs in the bulk tumor, as well as in TICs, is
required. Despite our limited knowledge of their func-
tions to date, early studies suggest that targeting KDM
activity may provide a new strategy for preventing PCa
relapse and progression.
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